Information Provided By: 
Fly News Breaks for July 19, 2017
ANGO
Jul 19, 2017 | 07:29 EDT
Canaccord analyst Jason Mills said he views AngioDynamics as a strong and improving cash flow story that should be on investors' radar and recommends becoming more constructive on the stock below $15 a share. While the analyst does not expect top-line growth over the next year, he does expect improving gross margins and strong free cash flow and believes M&A could be a positive driver for the shares. Mills maintained his Hold rating and raised his price target to $17 from $16.50
News For ANGO From the Last 2 Days
There are no results for your query ANGO
